TransCode Therapeutics Ownership | Who Owns TransCode Therapeutics?

TransCode Therapeutics Ownership Summary

TransCode Therapeutics is owned by 3.74% institutional investors, 1.78% insiders, and 94.48% retail investors. Ubs group is the largest institutional shareholder, holding 0.90% of RNAZ shares. Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund, with 0.65% of its assets in TransCode Therapeutics shares.

RNAZ Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	TransCode Therapeutics	3.74%	1.78%	94.48%
Sector	Healthcare Stocks	244.59%	12.11%	-156.70%
Industry	Biotech Stocks	379.61%	11.70%	-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Ubs group	8.29K	0.90%	$71.42K
Vanguard fiduciary trust	2.98K	0.33%	$25.68K
Tower research capital llc (trc)	228.00	0.02%	$1.96K
Wells fargo & company/mn	55.00	0.01%	$474.00
Sbi securities	12.00	0.00%	$103.00
Advisor group	-	-	-
Geode capital management	-	-	-

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Tower research capital llc (trc)	228.00	0.00%	$1.96K
Advisor group	-	-	-
Geode capital management	-	-	-
Wells fargo & company/mn	55.00	-	$474.00
Sbi securities	12.00	-	$103.00
Vanguard fiduciary trust	2.98K	-	$25.68K
Ubs group	8.29K	-	$71.42K

Top Buyers

Holder	Shares	% Assets	Change
Ubs group	8.29K	-	5.33K
Vanguard fiduciary trust	2.98K	-	2.98K
Wells fargo & company/mn	55.00	-	55.00
Sbi securities	12.00	-	2.00
Advisor group	-	-	-3.00

Top Sellers

Holder	Shares	% Assets	Change
Geode capital management	-	-	-12.74K
Tower research capital llc (trc)	228.00	0.00%	-659.00
Advisor group	-	-	-3.00
Sbi securities	12.00	-	2.00
Wells fargo & company/mn	55.00	-	55.00

New Positions

Holder	Shares	% Assets	Change	Value
Vanguard fiduciary trust	2.98K	-	2.98K	$25.68K
Wells fargo & company/mn	55.00	-	55.00	$474.00

Sold Out

Holder	Change
Advisor group	-3.00
Geode capital management	-12.74K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Jun 30, 2026	9	28.57%	35,039	13.55%	3	33.02%	4	-33.33%	1	-
Mar 31, 2026	5	-	17,889	362.01%	1	619.01%	5	150.00%	-	-
Dec 31, 2025	5	-28.57%	3,872	-73.16%	-	18.75%	2	-33.33%	-	-100.00%
Sep 30, 2025	7	-12.50%	14,426	-52.52%	1	13.03%	3	50.00%	1	-83.33%
Jun 30, 2025	8	-50.00%	30,382	-98.58%	3	0.79%	2	-87.50%	6	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Vanguard Institutional Extnd Mkt Idx Tr	6.54K	0.65%	-
Fidelity Extended Market Index	5.11K	0.48%	-3.38K
Spartan Extended Market Index Pool F	1.28K	0.12%	-
Fidelity Series Total Market Index	1.18K	0.11%	-
NT Ext Equity Mkt Index Fund - NL	832.00	0.09%	832.00
NT Ext Equity Mkt Idx Fd - DC - NL - T2	604.00	0.06%	604.00
NT Ext Eq Mkt Indx Fd DC Lend T3	394.00	0.06%	394.00
NT Ext Eq Mkt Indx Fd DC Lend T4	394.00	0.06%	394.00
Spartan Total Market Index Pool G	536.00	0.06%	-
Spartan Total Market Index Pool A1	536.00	0.05%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Sep 28, 2023	Fitzgerald Thomas A	Chief Financial Officer	Buy	$25.17K
Sep 28, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$49.98K
Jun 21, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$31.82K
Jun 20, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$16.85K
Jun 09, 2023	Dudley Robert Michael	Chief Executive Officer	Buy	$52.44K

Insider Transactions Trends

Date	Buy	Sell
2026 Q3	-	-
2025 Q4	-	-
2024 Q2	-	-
2023 Q3	2	-
2023 Q2	4	-

RNAZ Ownership FAQ

Who Owns TransCode Therapeutics?

TransCode Therapeutics shareholders are primarily institutional investors at 3.74%, followed by 1.78% insiders and 94.48% retail investors. The average institutional ownership in TransCode Therapeutics's industry, Biotech Stocks , is 379.61%, which TransCode Therapeutics falls below.

Who owns the most shares of TransCode Therapeutics?

TransCode Therapeutics’s largest shareholders are Ubs group (8.3K shares, 0.90%), Vanguard fiduciary trust (2.98K shares, 0.33%), and Tower research capital llc (trc) (228 shares, 0.02%). Together, they hold 1.25% of TransCode Therapeutics’s total shares outstanding.

Does Blackrock own TransCode Therapeutics?

BlackRock is not among the top 10 institutional shareholders of TransCode Therapeutics.

Who is TransCode Therapeutics’s biggest shareholder by percentage of total assets invested?

Tower research capital llc (trc) is TransCode Therapeutics’s biggest shareholder by percentage of total assets invested, with 0.00% of its assets in 228 TransCode Therapeutics shares, valued at 1.96K$.

Who is the top mutual fund holder of TransCode Therapeutics shares?

Vanguard Institutional Extnd Mkt Idx Tr is the top mutual fund holder of TransCode Therapeutics shares, with 0.65% of its total shares outstanding invested in 6.54K TransCode Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools